Psychopharmacology in children with PDD: Review of current evidence

Evidence-Based Practices and Treatments for Children with Autism

Volumn , Issue , 2011, Pages 231-243

  Scahill, Lawrence ^a   Boorin, Susan Griebell ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84862228888     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-6975-0_8     Document Type: Chapter

References (35)

1. Aman, M. G., Lam, K., & Collier-Crespin, A. (2003). Prevalence and patterns of use of psy-choactive medicines among individuals with autism in the autism society of Ohio. Journal of Autism and Developmental Disorders, 33(5), 527-534.
2. Aman, M. G., McDougle, C. J., Scahill, L., Handen, B., Arnold, L. E., et al. (2009). Medication and parent training in children with pervasive developmental disorders and serious behavioral problems: Results from a randomized clinical trial. Journal of the American Academy of Child and Adolescent Psychiatry, 48(12), 1143-1154.
3. APA. (2000). Diagnostic and Statistical Manual of Mental Disorders (4th ed.-text revision). washington, DC: American Psychiatric Association.
4. Biederman, J., Melmed, R. D., Patel, A., et al. (2008). A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-defcit/hyperactivity disorder. Pediatrics, 121(1), e73-e84.
5. Brown, E., Aman, M., & Havercamp, S. (2002). Factor analysis and norms for parent ratings on the Aberrant Behavior Checklist-Community for young people in special education. Research in Developmental Disabilities, 23, 45-60.
6. Bussing, R., Fernandez, M., Harwood, M., Hou, W., Garvan, C., & Eyberg, S. (2008). Parent and teacher SNAP-IV ratings of attention defcit hyperactivity disorder symptoms: Psychometric properties and normative ratings from a school district sample. Assessment, 15(3), 317-328.
7. Campbell, M., Anderson, L., & Cohen, I. (1982). Haloperidol in autistic children: effects on learning, behavior, and abnormal involuntary movements. Psychopharmacology Bulletin, 18(1), 110-111.
8. Fombonne, E. (2005). epidemiology of autistic disorder and other pervasive developmental disorders. Journal of Clinical Psychiatry, 66(Suppl. 10), 3-8.
9. Guy, W. (1976). ECDEU Assessment Manual for Psychopharmacology, revised. Rockville, MD: National Institute of Mental Health. on P. 243
10. Handen, B. L., Sahl, R., & Hardan, A. Y. (2008). Guanfacine in children with autism and/or intellectual disabilities. Journal of Developmental and Behavioral Pediatrics, 29(4), 303-308.
11. Hollander, E., Phillips, A., Chaplin, W., Zagur-sky, K., Novotny, S., & Wasserman, S. (2005). A placebo controlled crossover trial of liquid fuoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacol-ogy, 30(3), 582-589.
12. Horrigan, J. P., & Barnhill, L. J. (1995). Guanfa-cine for treatment of attention-defcit hyper-activity disorder in boys. Journal of Child and Adolescent Psychopharmacology, 5(3), 215-223.
13. Jaselskis, C., Cook, E., Fletcher, K., & Leven-thal, B. L. (1992). Clonidine treatment of hyperactive and impulsive children with autistic disorder. Journal of Clinical Psychopharmacology, 12, 322-327.
14. Johnson, C. R., Handen, B. L., Butter, E., Wagner, A., Mulick, J., & Sukhodolsky, D. G. (2007). Development of a parent management training program for children with pervasive developmental disorders. Behavioral Interventions, 22, 1-21.
15. King, B. H., Hollander, E., Sikich, L., McCracken, J. T., Scahill, L., et al. (2009). Lack of effcacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: Citalopram ineffective in children with autism. Archives of General Psychiatry, 66(6), 583-590.
16. Kolevzon, A., Mathewson, K., & Hollander, E. (2006). Selective serotonin reuptake inhibitors in autism: A review of effcacy and tolerability. Journal of Clinical Psychiatry, 67, 407-414.
17. Levy, S., & Hyman, S. (2005). Novel treatments for autistic spectrum disorders. Mental Retardation and Developmental Disabilities Research Reviews, 11, 131-142.
18. Luby, J., Mrakotsky, C., Salets, M., Belden, A., Heffelfnger, A., & Williams, M. (2006). Ris-peridone in preschool children with autistic disorders: An investigation of safety and eff-cacy. Journal of Child and Adolescent Psychophar-macology, 16(5), 575-587.
19. Mandell, D. S., Morales, K. H., Marcus, S. C., Stahmer, A. C., Doshi, J., & Polsky, D. E. (2008). Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders. Pediatrics, 121(3), e441-448.
20. McDougle, C. J., Scahill, L., Aman, M. G., McCracken, J. T., Tierney, E., et al. (2005). Risperidone for the core symptom domains of autism: Results from the RUPP Autism Network study. American Journal of Psychiatry, 162, 1142-1148.
21. MTA Cooperative Group. (1999). A 14-month randomized clinical trial of treatment strategies for attention-defcit/hyperactivity disorder. Archives of General Psychiatry, 56, 1073-1086.
22. Neuropharm Group. (2009). Phase III SOFIA study of NPL-2008 in Autistic Disorder. Retrieved August, 2009 from http://www.neuropharm.co.uk/media-centre/ news-release/?page = 2&id = 3542
23. Oswald, D. P., & Sonenklar, N. A. (2007). Medication use among children with autism spectrum disorders. Journal of Child and Adolescent Psy-chopharmacology, 17(3), 348-355.
24. Posey, D., Aman, M., McCracken, J., Scahill, L., Tierney, E., et al. (2007). Positive effects of methylphenidate on inattention and hyperac-tivity in pervasive developmental disorders: An analysis of secondary measures. Biological Psychiatry, 61(4), 538-544.
25. RUPP. (2002). Risperidone in children with autism and serious behavioral problems. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. New England Journal of Medicine, 347(5), 314-321.
26. RUPP. (2005a). Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Research Units on Pediatric Psychopharma-cology (RUPP) Autism Network. Archives of General Psychiatry, 62(11), 1266-1274.
27. RUPP. (2005b). Risperidone treatment of autistic disorder: longer term benefts and blinded discontinuation after six months. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. American Journal of Psychiatry, 162, 1361-1369.
28. RUPP. (2007). A pilot study of parent management training in children with pervasive developmental disorder. Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Behavioral Interventions, 22, 179-199.
29. Scahill, L., & Martin, A. (2005). Psychopharma-cology. In F. R. Volkmar, R. Paul, A. Klin, & D. J. Cohen (eds.), Handbook of Autism and Pervasive Developmental Disorders (3rd ed., pp. 1102-1117). Hoboken, NJ: wiley.
30. Scahill, L., Aman, M. G., McDougle, C. J., McCracken, J. T., Tierney, E., et al. (2006). A prospective open trial of guanfacine in children with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 16(5), 589-598.
31. Scahill, L., Aman, M., McDougle, C., Arnold, L., McCracken, J., & Handen, B. (2009). Trial design challenges when combining medication and parent training in children with pervasive developmental disorders. Journal of Autism and Developmental Disorders, 39(5), 720-729.
32. Scahill, L., Chappell, P. B., Kim, Y. S., Schultz, R. T., Katsovich, L., et al. (2001). A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention defcit hyperactivity disorder. American Journal of Psychiatry, 158(7), 1067-1074.
33. Scahill, L., McDougle, C. J., Williams, S. K., Dimitropoulos, A., Aman, M. G., et al. (2006). Children's Yale-Brown obsessive compulsive scale modifed for pervasive developmental disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 45(9), 1114-1123.
34. Scahill, L., Riddle, M. A., McSwiggin-Hardin, M., Ort, S. I., King, R. A., et al. (1997). Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity. Journal of the American Academy of Child and Adolescent Psychiatry, 36(6), 844-852.
35. Shea, S., Turgay, A., Carroll, A., Schulz, M., Orlik, H., et al. (2004). Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics, 114(5), e634-e641.